Hexima Ltd (HXL)

Sydney
0.38
+0.01(+4.11%)
  • Volume:
    37,487
  • Bid/Ask:
    0.37/0.38
  • Day's Range:
    0.37 - 0.38

HXL Overview

Prev. Close
0.37
Day's Range
0.37-0.38
Revenue
4.08M
Open
0.37
52 wk Range
0.14-0.5
EPS
-0.06
Volume
37,487
Market Cap
47.76M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
120,608
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
130,857,724
Next Earnings Date
-
What is your sentiment on Hexima Ltd?
or
Vote to see community's results!

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyNeutralStrong SellStrong Buy
SummaryBuyBuyNeutralNeutralStrong Buy

Hexima Ltd Company Profile

Hexima Ltd Company Profile

Sector
Services
Employees
0
Market
Australia

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company’s lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. The company was incorporated in 1997 and is headquartered in Melbourne, Australia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.